
Filed by Big Cypress Acquisition Corp.
pursuant to Rule 425 under the Securities Act of 1933
and deemed filed pursuant to Rule 14a-12
under the Securities Exchange Act of 1934
Subject Company: Big Cypress Acquisition Corp.
Commission File No.: 001-39871
Date: September 27, 2021





\$BCYP ACTG announces graduation of novel polyclonal antibody therapy SAB-185 to phase 3 study in ACTIV-2





## Samuel Reich

Chief Executive Officer at Big Cypress **Acquisition Corp** now • 🕥

Congrats to \$BCYP merger partner SAB!



Eddie J Sullivan · 1st President/CEO at SAB Biotherapeutics, Inc. 48m · 🕥

We appreciate the work and collaboration of ACTG in these clinical trials as the result of the graduation of SAB-185 to phase 3 clinical trials is ...see more

ACTG announces graduation of novel polyclonal antibody therapy SAB-185 to p...

eurekalert.org • 4 min read

The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, which recently expanded its foc...









Share